DRMA
Dermata Therapeutics·NASDAQ
--
--(--)
--
--(--)
DRMA fundamentals
During Q4 2025, Dermata Therapeutics (DRMA) reported revenue of --, a YoY change of 0.00%. Net income was -1.86M, a YoY change of 40.91%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2020 | Q2,2020 | Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2020 | Apr 1, 2020 | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2020 | Jun 30, 2020 | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 1.35M -- | 792.79K -- | 540.06K -- | 491.43K -- | 2.26M +67.72% | 1.33M +67.76% | 1.71M +217.05% | 2.55M +419.48% | 2.79M +23.18% | 2.73M +105.31% | 2.45M +42.86% | 1.71M -32.95% | 2.28M -18.25% | 1.73M -36.55% | 1.81M -25.92% | 2.22M +29.69% | 3.20M +40.65% | 2.88M +66.46% | 3.23M +78.02% | 3.20M +44.17% | 2.34M -26.96% | 1.77M -38.53% | 1.76M -45.42% | 1.90M -40.62% | 7.77M -- |
Selling, General and Administrative Expenses | 387.47K -- | 380.84K -- | 419.60K -- | 377.13K -- | 1.58M +308.08% | 462.77K +21.51% | 912.49K +117.47% | 1.44M +282.12% | 1.19M -24.72% | 1.12M +141.59% | 892.78K -2.16% | 822.33K -42.94% | 1.09M -8.84% | 893.48K -20.08% | 909.00K +1.82% | 1.08M +31.89% | 1.60M +47.72% | 874.64K -2.11% | 824.29K -9.32% | 1.01M -7.08% | 1.06M -33.95% | 1.15M +32.04% | 1.26M +52.41% | 1.37M +36.31% | 4.84M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | 1.57M -- | -- -- | -- -- | -- -- | 4.40M +180.99% | -- -- | -- -- | -- -- | 4.02M -8.51% | -- -- | -- -- | 909.00K -- | 1.08M -73.04% | 1.60M -- | 874.64K -- | -- -- | -- -- | 1.06M -33.95% | 1.15M +32.04% | -- -- | -- -- | -- -- |
Research and Development Expenses | 961.10K -- | 411.95K -- | 120.47K -- | 114.30K -- | 680.59K -29.19% | 867.20K +110.51% | 799.78K +563.90% | 1.11M +872.69% | 1.60M +134.48% | 1.61M +85.95% | 1.55M +94.22% | 889.36K -20.01% | 1.19M -25.27% | 838.93K -47.97% | 902.98K -41.87% | 1.14M +27.65% | 1.60M +34.22% | 2.01M +139.48% | 2.40M +165.94% | 2.19M +93.13% | 1.28M -19.97% | 617.84K -69.25% | 504.39K -79.00% | 526.62K -75.98% | 2.93M -- |
Operating Income | -1.35M -- | -792.79K -- | -540.06K -- | -491.43K -- | -2.26M -67.72% | -1.33M -67.76% | -1.71M -217.05% | -2.55M -419.48% | -2.79M -23.18% | -2.73M -105.31% | -2.45M -42.86% | -1.71M +32.95% | -2.28M +18.25% | -1.73M +36.55% | -1.81M +25.92% | -2.22M -29.69% | -3.20M -40.65% | -2.88M -66.46% | -3.23M -78.02% | -3.20M -44.17% | -2.34M +26.96% | -1.77M +38.53% | -1.76M +45.42% | -1.90M +40.62% | -7.77M -- |
Non-Operating Income (Loss) | -72.60K -- | -28.86K -- | -57.33K -- | 95.11K -- | -43.13K +40.58% | -1.82K +93.68% | -651 +98.86% | 0 -100.00% | 0 +100.00% | 0 +100.00% | 21.49K +3400.46% | 42.09K -- | 37.54K -- | 31.05K -- | 92.77K +331.76% | 85.86K +104.00% | 69.30K +84.60% | 54.64K +75.96% | 52.50K -43.41% | 49.35K -42.52% | 36.22K -47.74% | 71.64K +31.12% | 68.68K +30.83% | 38.51K -21.98% | 215.04K -- |
Gain (Loss) on Other Investment | -- -- | -- -- | -- -- | 133.59K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | 72.60K -- | 28.86K -- | 57.33K -- | 38.48K -- | 43.13K -40.58% | 1.82K -93.68% | 651 -98.86% | 0 -100.00% | 0 -100.00% | 0 -100.00% | -21.49K -3400.46% | -42.09K -- | -37.54K -- | -31.05K -- | -92.77K -331.76% | -85.86K -104.00% | -69.30K -84.60% | -54.64K -75.96% | -52.50K +43.41% | -49.35K +42.52% | -36.22K +47.74% | -71.64K -31.12% | -68.68K -30.83% | -38.51K +21.98% | -215.04K -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 21.49K -- | 42.09K -- | 37.54K -- | 31.05K -- | 92.77K +331.76% | 85.86K +104.00% | 69.30K +84.60% | 54.64K +75.96% | 52.50K -43.41% | 49.35K -42.52% | 36.22K -47.74% | 71.64K +31.12% | 68.68K +30.83% | 38.51K -21.98% | 215.04K -- |
Pretax Income From Continuing Operations | -1.42M -- | -821.65K -- | -597.39K -- | -396.31K -- | -2.30M -62.18% | -1.33M -62.09% | -1.71M -186.73% | -2.55M -544.15% | -2.79M -20.88% | -2.73M -105.03% | -2.42M -41.55% | -1.67M +34.60% | -2.24M +19.60% | -1.70M +37.69% | -1.72M +29.09% | -2.13M -27.81% | -3.13M -39.91% | -2.83M -66.28% | -3.17M -84.57% | -3.15M -47.66% | -2.30M +26.50% | -1.70M +39.87% | -1.69M +46.68% | -1.86M +40.91% | -7.56M -- |
Income Tax Expense | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -1.42M -- | -821.65K -- | -597.39K -- | -396.31K -- | -2.30M -62.18% | -1.33M -62.09% | -1.71M -186.73% | -2.55M -544.15% | -2.79M -20.88% | -2.73M -105.03% | -2.42M -41.55% | -1.67M +34.60% | -2.24M +19.60% | -1.70M +37.69% | -1.72M +29.09% | -2.13M -27.81% | -3.13M -39.91% | -2.83M -66.28% | -3.17M -84.57% | -3.15M -47.66% | -2.30M +26.50% | -1.70M +39.87% | -1.69M +46.68% | -1.86M +40.91% | -7.56M -- |
Net Income Attributable to Owners of the Company | -1.42M -- | -821.65K -- | -597.39K -- | -396.31K -- | -2.30M -62.18% | -1.33M -62.09% | -1.71M -186.73% | -2.55M -544.15% | -2.79M -20.88% | -2.73M -105.03% | -2.42M -41.55% | -1.67M +34.60% | -2.24M +19.60% | -1.70M +37.69% | -1.72M +29.09% | -2.13M -27.81% | -3.13M -39.91% | -2.83M -66.28% | -3.17M -84.57% | -3.15M -47.66% | -2.30M +26.50% | -1.70M +39.87% | -1.69M +46.68% | -1.86M +40.91% | -7.56M -- |
Preferred Stock Dividends | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | 2.56M -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income Attributable to Common Stockholders | -1.42M -- | -821.65K -- | -597.39K -- | -396.31K -- | -2.30M -62.18% | -1.33M -62.09% | -4.28M -615.63% | -2.55M -544.15% | -2.79M -20.88% | -2.73M -105.03% | -2.42M +43.29% | -1.67M +34.60% | -2.24M +19.60% | -1.70M +37.69% | -1.72M +29.09% | -2.13M -27.81% | -3.13M -39.91% | -2.83M -66.28% | -3.17M -84.57% | -3.15M -47.66% | -2.30M +26.50% | -1.70M +39.87% | -1.69M +46.68% | -1.86M +40.91% | -7.56M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -1.42M -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -1.42M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -2.83M -- | -- -- | -- -- | -- -- | -1.70M +39.87% | -- -- | -- -- | -- -- |
Basic EPS | -0.74 -- | -0.43 -- | -0.31 -- | -- -- | -1.21 -63.51% | -0.7 -62.79% | -0.86 -177.42% | -0.31 -- | -5.35 -342.15% | -3.9 -457.14% | -3.16 -267.44% | -0.14 +54.84% | -2.27 +57.57% | -9.43 -141.79% | -8.09 -156.01% | -0.54 -285.71% | -7.06 -211.01% | -41.82 -343.48% | -20.41 -152.29% | -1.25 -131.48% | -0.45 +93.63% | -1.66 +96.03% | -1.65 +91.92% | -0.7 +44.00% | -4.46 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -8.09 -- | -- -- | -7.06 -- | -41.82 -- | -20.41 -152.29% | -- -- | -0.45 +93.63% | -1.66 +96.03% | -1.65 +91.92% | -- -- | -- -- |
Diluted EPS | -0.74 -- | -0.43 -- | -0.31 -- | -- -- | -1.21 -63.51% | -0.7 -62.79% | -0.86 -177.42% | -- -- | -5.35 -342.15% | -3.9 -457.14% | -3.16 -267.44% | -- -- | -2.27 +57.57% | -9.43 -141.79% | -8.09 -156.01% | -- -- | -7.06 -211.01% | -41.82 -343.48% | -20.41 -152.29% | -- -- | -0.45 +93.63% | -1.66 +96.03% | -1.65 +91.92% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -8.09 -- | -- -- | -7.06 -- | -41.82 -- | -20.41 -152.29% | -- -- | -0.45 +93.63% | -1.66 +96.03% | -1.65 +91.92% | -- -- | -- -- |
You can ask Aime
What guidance did Dermata Therapeutics's management provide for the next earnings period?What is the market's earnings forecast for Dermata Therapeutics next quarter?What is the revenue and EPS growth rate for Dermata Therapeutics year over year?What is Dermata Therapeutics's latest dividend and current dividend yield?What is Dermata Therapeutics's gross profit margin?What does Dermata Therapeutics do and what are its main business segments?What were the key takeaways from Dermata Therapeutics's earnings call?Did Dermata Therapeutics beat or miss consensus estimates last quarter?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
